Clinical Trials - April 1, 2015
Antipsychotic Shows Promise
Three-month paliperidone palmitate, an investigational atypical antipsychotic developed by Janssen Research & Development, LLC, significantly delayed relapse time compared with a placebo in patients with schizophrenia, according to a new Phase 3 clinical study recently published in the Journal of the American Medical Association (JAMA) Psychiatry. Results of the study served as the basis for […]
Uncategorized - February 20, 2015
Brain Suffers if Sleep Deprived
Scientists are further researching the idea that brains “cleanse” themselves of waste proteins during sleep and too little sleep could contribute to diseases such as Alzheimer’s, schizophrenia, depression and ADHD. A research team, lead by Professor Maiken Nedergaard from the University of Rochester Medical Center, made a huge breakthrough in sleep research in 2013, when Nedergaard and […]
Uncategorized - August 7, 2014
New findings on schizophrenia
Researchers have identified more than 100 positions in the human genome that can be connected to the risk of developing schizophrenia. An international research team, where scientists from Umeå University and Karolinska Institute take part, have presented a new study in Nature on the findings which could lead to new methods to treat the disease. […]
Drug Development Pharma - September 25, 2013
Otsuka and Lundbeck receive positive CHMP opinion for Abilify Maintena(r) in schizophrenia
Lundbeck and Otsuka today announced a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation for the maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole. “Abilify Maintena has been available in the US for […]
